163 related articles for article (PubMed ID: 22506594)
1. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
[TBL] [Abstract][Full Text] [Related]
2. Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Zang T; Verma K; Chen M; Jin Y; Trippier PC; Penning TM
Chem Biol Interact; 2015 Jun; 234():339-48. PubMed ID: 25555457
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
[TBL] [Abstract][Full Text] [Related]
4. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
5. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
[TBL] [Abstract][Full Text] [Related]
7. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
8. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
9. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
Byrns MC; Jin Y; Penning TM
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
[TBL] [Abstract][Full Text] [Related]
11. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
13. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
[TBL] [Abstract][Full Text] [Related]
14. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
[TBL] [Abstract][Full Text] [Related]
16. Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Winkler JD; Penning TM
Bioorg Med Chem Lett; 2011 Mar; 21(5):1464-8. PubMed ID: 21277203
[TBL] [Abstract][Full Text] [Related]
17. 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
Jamieson SM; Brooke DG; Heinrich D; Atwell GJ; Silva S; Hamilton EJ; Turnbull AP; Rigoreau LJ; Trivier E; Soudy C; Samlal SS; Owen PJ; Schroeder E; Raynham T; Flanagan JU; Denny WA
J Med Chem; 2012 Sep; 55(17):7746-58. PubMed ID: 22877157
[TBL] [Abstract][Full Text] [Related]
18. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
19. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
20. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
